Lilly and Resilience Signal a Multi-Year Squeeze on Indiana Technical Labor

Indianapolis-headquartered Eli Lilly and contract manufacturer Resilience announced a $750 million joint investment on July 30 to add KwikPen injectable device production near Cincinnati, Ohio, creating at least 400 high-skilled jobs with full operations expected in early 2027. This runs parallel to Lilly's $4.5 billion, two-site Indiana expansion announced in May 2026.

The structural driver is Novo Nordisk's $11 billion acquisition of three former Catalent fill-finish sites, one of them in Bloomington, which pulled sterile injectable capacity off the open market just as GLP-1 demand accelerated. For Indiana operators, the indicator is labor. The same demand wave filling Resilience's Ohio campus is driving Lilly's Indiana buildout, and Indiana's sterile manufacturing, device assembly, and cGMP-trained technician pool is entering a multi-year demand surge that will pressure wages and training pipelines statewide.